Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;57(11):1326-1334.
doi: 10.1111/apt.17454. Epub 2023 Mar 10.

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease

Freddy Caldera  1 , Aaron C Spaulding  2 , Bijan Borah  3   4 , Jim Moriarty  4 , Ye Zhu  4 , Mary S Hayney  5 , Francis A Farraye  6
Affiliations

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease

Freddy Caldera et al. Aliment Pharmacol Ther. 2023 Jun.

Abstract

Background: Recombinant zoster vaccine (RZV) is recommended for all adults ≥19 years of age who are at increased risk for HZ, including patients with inflammatory bowel disease (IBD).

Methods: A Markov model was constructed to compare the RZV cost-effectiveness with no vaccination in patients with Crohn's Disease (CD) and ulcerative colitis (UC). A simulated cohort of 1 million patients was used for each IBD group at ages 18, 30, 40, and 50. The primary objective of this analysis was to compare RZV cost-effectiveness in patients with CD and UC, comparing vaccination to no vaccination.

Results: Overall, vaccination is cost-effective for both CD and UC, with the incremental cost-effectiveness ratio (ICERs) below $100,000/quality-adjusted life years (QALY) for all age cohorts. For patients with CD, 30 years of age and older, and those with UC 40 years and older, vaccination was both more effective and less expensive than the non-vaccinated strategy (CD ≥30: ICERs $6183-$24,878 and UC ≥40: ICERs $9163-$19,655). However, for CD patients under 30 (CD 18: ICER $2098) and UC patients under 40 (UC = 18: ICER $11,609, and UC = 30: $1343), costs were greater for vaccinated patients, but there was an increase in QALY. One-way sensitivity analysis of age indicates that cost break-even occurs at age 21.8 for the CD group and 31.5 for the UC group. In probabilistic sensitivity analysis, 92% of both CD and UC simulations indicated that vaccination was preferred.

Conclusion: In our model, vaccination with RZV was cost-effective for all adult patients with IBD.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Caldera F, Hayney MS, Farraye FA. Vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2020;115(9):1356-61.
    1. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(Rr-5):1-30. quiz CE32-34.
    1. Caldera F, Wald A, Saha S, Smith R, McCrone S, Farraye FA, et al. Equivalent cellular and humoral immunity to varicella zoster virus in patients with inflammatory bowel disease and healthy older adults for whom immunization is recommended. Clin Transl Gastroenterol. 2022;13(1):e00446.
    1. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6(6):356-63.
    1. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Cmaj. 2010;182(16):1731-6.

MeSH terms

LinkOut - more resources